Outcomes with empagliflozin in heart failure with preserved ejection fraction using DELIVER-like endpoint definitions

Autor: Anker, S.D. Siddiqi, T.J. Filippatos, G. Zannad, F. Ferreira, J.P. Pocock, S.J. Brueckmann, M. Zeller, C. Packer, M. Butler, J.
Jazyk: angličtina
Rok vydání: 2022
Popis: Aims: To report data from EMPEROR-Preserved according to prespecified endpoints of DELIVER. Methods and results: In order to assess the impact of DELIVER-like definition on EMPEROR-Preserved outcomes, the following differences were reconciled: (1) the primary outcome in DELIVER added urgent heart failure (HF) visits to cardiovascular death or HF hospitalizations; (2) the EMPEROR-Preserved trial did not require documentation of physical findings or laboratory tests for confirming a HF hospitalization and it included events of 12–24 h if intensification of treatment was not only oral diuretics; (3) DELIVER excluded undetermined causes of deaths from the primary endpoint; (4) the composite renal endpoint in DELIVER included a sustained ≥50% decline in estimated glomerular filtration rate and incorporated renal death; and (5) DELIVER will assess outcomes in the overall population and in patients with ejection fraction (EF)
Databáze: OpenAIRE